Ruxolitinib from MedChemExpress

Product Specs
ItemRuxolitinib
CompanyMedChemExpress
Price $79.00Supplier Page View Company Product Page
Catalog NumberHY-50856
Quantity10 mM * 1 mL
ApplicationsBioactivity, Structure and function analysis, ELISA, SDS-PAGE, Western blotting
Purity99.99%
TypeChemical
Molecular Weight306.37
Molecule NameRuxolitinib
FormulaC17H18N6
Research AreaCancer

Add to Compare List

MedChemExpress

1 Deer Park Drive, Suite F

MONMOUTH JUNCTION, NJ 08852

United States

Phone: US Tel: 609-228-6898
US Fax: 609-228-5909
EU Tel: +4686500910

Email: sales@medchemexpress.com
eu.sales@MedChemExpress.com

Company Profile

Website: medchemexpress.com

(1) Ruxolitinib reverses alopecia areata via a triple mechanism: JAK-STAT inhibition, localized oxidative stress attenuation and selective apoptosis modulationJournal of Translational AutoimmunityJune 1, 2026Meiling Zhu, Hao Mu, Bo Wang, Mengting Han, Zhao Ma, Xiaopan Nie, Tong Wang, Liyuan Zhang, Feng Lianggroup): the AA group (vehicle-treated) and the ruxolitinib-treated group (50 mg/kg/day; MedChemExpress, HY-50856). An additional 8 age-matched healthy mice served as the control group and were treated with vehicle.

(2) HE4 drives PD-L1 expression in myeloid cells via IFN-γR-JAK-STAT3 signaling to promote tumor immune evasionCell Reports MedicineApril 21, 2026Bo Zeng, Yingying Zhou, Heping Wang, Panyin Shu, Ting Pan, Fangfang Liu, Yangyang Li, Ming Yi, Ruirui He, Lingyun Feng, et al.HY-13319 PD169316,MedChemExpress,Cat# HY-10578 paclitaxel,MedChemExpress,Cat# HY-B0015 ruxolitinib,MedChemExpress,Cat# HY-50856 erlotinib,MedChemExpress,Cat# HY-50896 HIF-1α-IN,MedChemExpress,Cat# HY-115903 Recombinant Fc-tagged

(3) Elevated IgG levels induce an M2‑to‑M1 phenotypic shift in mucosal macrophages and restrict the growth of invasive sphenoid sinus pituitary adenomasMol Med RepApril 14, 2026Xingbo Li, Zhuowei Lei, Sihan Li, Linpeng Xu, Quanji Wang, Qian Jiang, Zihan Wang, Huaqiu Zhang, Yimin Huang, Ting Lei48 h at 37°C. Cells treated with ruxolitinib alone were incubated with ruxolitinib (5 µM; cat. no. HY-50856; MedChemExpress) for 48 h at 37°C. For combination treatments, cells were pretreated with ruxolitinib

(4) RIG‐I Mediated Neuron‐Specific IFN Type 1 Signaling in FUS‐ALS Induces Neurodegeneration and Offers New Biomarker‐Driven Individualized Treatment Options for (FUS‐)ALSAdvanced ScienceMarch 1, 2026Marcel Naumann, Theresa M. Wierschin, Stefanie Kretschmer, Banaja P. Dash, Aaron Held, Andrea Salzinger, Kevin Peikert, Anže Karlek, Hannes Glaß, Dajana Großmann, et al.resuspended to a final stock of 20 µg/mL in sterile aqua dest. Ruxolitinib was obtained from MedChemExpress (HY‐50856) and dissolved in DMSO for a 10 mM stock. The STING inhibitor H151 was obtained from Tocris (6675) and

(5) Combination of artesunate and ruxolitinib suppresses T cell leukemia/lymphoma proliferation via the JAK STAT pathwayScientific ReportsFebruary 11, 2026Yupei Yuan, Yan Li, Jie Li, Shuyu Wang, Fuyi Luo, Chen Huang, Jie Yang, Yujing Hu, Youchao Jia, Suyun Wangand positive expression of DAB was brownish yellow. Drugs Artesunate (HY-N0193) and ruxolitinib (HY-50856) were purchased from MedChemExpress (Monmouth Junction, NJ, USA). The initial concentration of artesunate

(6) Natural polysaccharide riclin acts as an immune adjuvant to enhance chemotherapy efficacy in NSCLCnpj Precision OncologyFebruary 4, 2026Yaqiong Miao, Xiaofen Liu, Jing Tao, Yang Jiao, Yizhuo Fan, Xiaqing Sun, Junhao Liu, Zhao Ding, Jianfa Zhang, Qin Gao, et al.inhibitor, HY-13453, MedChemExpress LLC, 5 mg/kg, i.p.), and riclin + Ruxolitinib (JAK2 inhibitor, HY-50856, MedChemExpress LLC, 60 mg/kg, p.o.). The inhibitors were administered 30 min prior to riclin gavage.

(7) Dysregulation of YTHDF2 promotes the over expression of interferon beta in anti-MDA5 antibody-positive dermatomyositisArthritis Research & TherapyJanuary 24, 2026Mengxiao Zhang, Qishun Geng, Xing Wang, Xiaoxue Cao, Sang Lin, Qiwen Jin, Yi Jiao, Qinglin Peng, Cheng Xiao37 °C and 5% CO2. For Ruxolitinib-treated samples, THP-1 cells were cultured with 1 µM Ruxolitinib (HY-50856, MedChemExpress, USA) for 24 h [24]. For all treatment experiments, THP-1 cells were seeded in 6-well

(8) Extracellular Lipopolysaccharide Triggers the Release of Unconjugated Interferon-Stimulated Gene 15 (ISG15) Protein from Macrophages via Type-I Interferon/Caspase-4/Gasdermin-D PathwayPathogensJanuary 22, 2026Sudiksha Pandit, Lindsay Grace Miller, Indira Mohanty, Santanu Bose(1 µM; MedChemExpress, catalog number—HY-11109), Ruxolitinib (1 µM; MedChemExpress, catalog number—HY-50856), and 3-Methyladenine (3MA) (10 µM; Sigma-Aldrich, catalog number—5142-23-4). Following pre-treatment,

(9) Identification of Novel JAK2 Inhibitors from Amino Derivatives of Epoxyalantolactone: In Silico and In Vitro StudiesInternational Journal of Molecular SciencesDecember 28, 2025Duangjai Todsaporn, Kamonpan Sanachai, Chanat Aonbangkhen, Rungtiva P. Poo-arporn, Victor Kartsev, Sergey Pukhov, Svetlana Afanasyeva, Athina Geronikaki, Thanyada Rungrotmongkol(Cat. No. SRP0171). Ruxolitinib was obtained from MedChemExpress, Monmouth Junction, NJ, USA (Cat. No. HY-50856). MTT was from Sigma-Aldrich, St. Louis, MO, USA. (Cat. No. M2128). Dimethyl sulfoxide (DMSO) was obtained

(10) VAPB is a negative regulator of STING-mediated innate immune signalingSci AdvDecember 5, 2025Wangsheng Ji, Yin Zhang, Lianfei Zhang, Qingqing Liu, Shengbo Niu, Yuqun Feng, Feilong Chen, Xinqi Liu, Xia Lianti-rabbit IgG-HRP (1:10,000; Sigma-Aldrich, AP132, Western blotting). Go6983 (HY-13689) and Ruxolitinib (HY-50856) were purchased from MedChemExpress. 2′,3′-cGAMP (tlrl-nacga23) was purchased from InvivoGen. Biotin-cGAMP

(11) TSN Disrupts Fanconi Anemia Pathway Activation Through JAK/STAT1-Mediated Transcriptional Repression of FA Core Subunits in Bladder CancerDose ResponseDecember 2, 2025Wenchao Zhao, Zhiyuan Xie, Liang Zhu, Wenqi Li(TSN, purity ≥98%, HY-N0263, MedChemExpress, China) for 24 h, 1 μM JAK/STAT1 inhibitor Ruxolitinib (HY-50856, MedChemExpress) for 24 h, 20 ng/mL JAK/STAT1 agonist interferon-gamma (IFN-γ, HY-P73252, MedChemExpress)

(12) Autonomous STING signaling in Purkinje cells drives neurodegeneration independent of type I interferonCell ReportsNovember 25, 2025Kun Yang, Miranda Dunn, Gustavo Torres-Ramirez, Nicole Dobbs, Vikram G. Shakkottai, Nan YanMgATP, 0.3 tris-GTP, pH 7.3, osmolarity 290 mOsm. JAK inhibitor Ruxolitinib (MedChemExpress, Cat. No.: HY-50856) was used at 10 μM for assessing somatic spiking in Purkinje Cells. CRAC inhibitor GSK-7975A (MilliporeSigma)

(13) DNA fragmentation factor B suppresses interferon to enable cancer persister cell regrowthNature Cell BiologyNovember 17, 2025August F. Williams, David A. G. Gervasio, Claire E. Turkal, Anna E. Stuhlfire, Michael X. Wang, Brandon E. Mauch, Rhea Plawat, Ariel H. Nguyen, Michelle H. Paw, Mehrshad Hairani, et al.(PBS) (SCT105) and cytochalasin B (C2743) were purchased from Sigma-Aldrich. JAK inhibitor ruxolitinib (HY-50856), TBK1 inhibitor MRT67307 (HY-13018), thapsigargin (HY-13433), ABT-737 (HY-50907), S63845 (HY-100741)

(14) ZNF334 truncation mutation drives cold-induced autoinflammationEMBO Molecular MedicineOctober 30, 2025Joung-Liang Lan, Shih-Hsin Chang, Yi-Hua Lai, Ju-Pi Li, Guan-Jun Chen, Yen-Ju Lin, Ya-Ling Huang, Bor-Luen Chiang, Jan-Gowth Chang, Guan-Yun Lu, et al.Fisher Scientific,A44449 Universal Magnetic Co-IP kit,Active Motif,54002 Ruxolitinib,MedChemExpress,HY-50856 qEV,Izon Science,IC1-70 DNA Sample Preparation Kit,Roche Diagnostics,05985536190 2X KAPA2G Fast Multiplex

(15) Therapeutic targeting of STING-IL6/STAT3 axis to inhibit osteoclastic niche formation and breast cancer bone metastasisCell Death DiscovOctober 24, 2025Chen Zhao, Pengcheng Liu, Keyu Kong, Xuzhuo Chen, Junxiang Wu, Wen Wu, Xiaoqing Wang, Lei WangLiving Image software (Xenogen). Pharmacological compounds DMXAA (HY-10964, MCE) and Ruxolitinib (HY-50856) were procured from MCE (MedChemExpress). All pharmacological compounds were prepared according to the

(16) CD44 Participates to Extramedullary Haematopoiesis Onset by Mediating the Interplay Between Monocytes and Haematopoietic Stem Cells in MyelofibrosisJ Cell Mol MedJuly 21, 2025Margherita Mirabile, Camilla Tombari, Anita Neroni, Lara Tavernari, Ruggiero Norfo, Elisa Bianchi, Monica Maccaferri, Barbara Mora, Sandra Parenti, Chiara Carretta, et al.Hyaluronan inhibitor (cat. #AS‐62622, Anaspec, California, USA). We used also Ruxolitinib (INCB18424, cat# HY‐50856, MedChemExpress, Monmouth Junction, NJ, USA), resuspended in dimethyl sulfoxide (DMSO, Sigma‐Aldrich,

(17) Aberrant activation of IL-6/JAK/STAT3/FOSL1 signaling induces renal abnormalities in a Xenopus model of Joubert syndrome-related disordersJournal of Biological ChemistryJune 24, 2025Udval Uuganbayar, Hiromasa Ninomiya, Issei S. Shimada, Chisato Yamada, Mayu Kanie, Shinji Kawai, Takahiro Asai, Toru Miyoshi-Akiyama, Masayuki Itoh, Yutaka Hashimoto, et al.solutions as follows. Tolvaptan (50 mM, Sigma-Aldrich, T7455), ruxolitinib (10 mM, MedChemExpress, HY-50856), and dexamethasone (20 mM, Nacalai Tesque, 11,107–64). The stock solutions were diluted for treating

(18) Innate immunity and the NF-κB pathway control prostate stem cell plasticity, reprogramming and tumor initiationNature CancerJune 23, 2025Chen Jiang, Yura Song, Sandrine Rorive, Justine Allard, Elisavet Tika, Zahra Zahedi, Christine Dubois, Isabelle Salmon, Alejandro Sifrim, Cédric Blanpain6mg/kg body weight, MedChemExpress, HY-13982), Ruxolitinib (i.p., 10mg/kg body weight, MedChemExpress, HY-50856) and Anakinra (i.p., 10mg/kg body weight, Sobi, Kineret) were injected into mice. Rapamycin was firstly

(19) Tumor suppressor SLC9A2 inhibits colorectal cancer metastasis and reverses immunotherapy resistance by suppressing angiogenesisJ Exp Clin Cancer ResJune 5, 2025Zizhen Zhang, Shengde Liu, Ting Xu, Nan Chen, Cheng Liu, Hong Yang, Yuanmeng Shi, Zhiwei Li, Xujiao Feng, Yanhong Yao, et al.− 3′. The p-STAT3Y705 inhibitor Stattic (MCE, HY-13818) and the JAK1/2 inhibitor Ruxolitinib (MCE, HY-50856) were utilized in this study. Western blot Proteins of Cells or PDOs were lysed and harvested then

(20) Sensitivity to immune checkpoint inhibitors in BRAF/MEK inhibitor refractory melanomaJ Immunother CancerMay 15, 2025Riyaben P Patel, Lydia Rui Jia Lim, Reem Saleh, Darius Schenk, Michael K Lee, Emily Lelliott, Aparna D Rao, Shaghayegh Arabi, Lorey Smith, Anna S Trigos, et al.HY-13919), 1 µM of AC-4–130 (STAT5i: MCE, cat no. HY-124500) and 2 µM of ruxolitinib (MCE, cat no. HY-50856). DMSO (Dimethyl sulfoxide) was used as a vehicle for all in vitro drug assays. Animal models, in vivo

Be the First to Write a Review!

Ruxolitinib from MedChemExpress

Description

MedChemExpress

Citations (61)

Reviews

Ruxolitinib from MedChemExpress

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map